ArticleFrontiers in cellular and infection microbiology2021
Molecular Epidemiology of Hypervirulent Carbapenemase-Producing
Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- RecCVirulence · 2026Article
- Molecular epidemiological characteristics of carbapenem-resistant Enterobacter cloacae complex.Scientific reports · 2026Article
- Urinary Multidrug-ResistantMicroorganisms · 2025Article
- Genomic characteristics, virulence potential, antimicrobial resistance profiles, and phylogenetic insights into Nocardia cyriacigeorgica.Annals of clinical microbiology and antimicrobials · 2025Article
- Genomic characteristics and phylogenetic analyses of colonization and infection with carbapenem-resistantMicrobiology spectrum · 2025Article
- Molecular and genetic features of a blaAnnals of clinical microbiology and antimicrobials · 2025Article
- Prevalence and molecular characteristics of colistin-resistant isolates among carbapenem-resistant Klebsiella pneumoniae in Central South China: a multicenter study.Annals of clinical microbiology and antimicrobials · 2025Article
- In vitro Evaluation of the Antibacterial Activity of the Combination of Avibactam and β-Lactams Against Highly Virulent Carbapenem-ResistantInfection and drug resistance · 2025Article
- The Association between Resistance and Virulence ofMicroorganisms · 2024Article
- Virulence Factors inIndian journal of microbiology · 2024Review
- Development of a quadruple qRT-PCR assay for simultaneous identification of hypervirulent and carbapenem-resistantMicrobiology spectrum · 2024Article
- Analysis of virulence profiles in clinical isolates ofFrontiers in cellular and infection microbiology · 2024Article
- Genetic and Functional Analysis of theMicrobiology spectrum · 2023Article
- [UhpTNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Functional Characterization of Plasmid-BorneMicrobiology spectrum · 2023Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- The making of hypervirulent Klebsiella pneumoniae.Journal of clinical laboratory analysis · 2022Review
- Pyogenic liver abscess-caused Klebsiella pneumoniae in a tertiary hospital in China in 2017: implication of hypervirulent carbapenem-resistant strains.BMC infectious diseases · 2022Article
- Prostatic Abscess Caused byJournal of clinical medicine · 2022Article
- Antimicrobial Susceptibility, Virulence, and Genomic Features of a Hypervirulent Serotype K2, ST65Antibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the overall distributions of key virulence genes in Methods: A total of 521 complete genomes of Results: Positive rates of virulence genes highly varied, ranging from 2.9 ( Conclusions: Positive rates of virulence genes vary remarkably in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.